Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.

Reply to this topic

post Posted: Aug 24 2019, 03:49 PM
  Quote Post

Posts: 2,101
Thanks: 154

In Reply To: maru's post @ Apr 15 2016, 12:13 AM

maru: NO postings on this most interesting stock! I have bought a small position not too long ago, as an exciting period is ahead for PTX for certain!!


post Posted: Apr 15 2016, 12:13 AM
  Quote Post

Posts: 9

In Reply To: maru's post @ Apr 4 2016, 02:17 AM

From this weeks presentation

Investment Summary: Why all the excitement about AML?

• Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need. » One of the worst survival rates of all cancers » Standard of care unchanged in 40 years

• A disease of intense interest for clinicians, pharma companies and investors

• Celator Pharmaceuticals (NASDAQ: CPXX) showed what can happen when enhancing the standard of care in AML » Market cap recently surged from small cap to $780M » Dr Jeff Lancet was the Principal Investigator on CPXX’s ground-breaking trial

• PTX had successful Phase 1 trial in AML (conducted at Moffitt and MD Anderson)

• Dr Lancet is also the Principal Investigator on PTX’s imminent Phase 1b/2 AML trial

• AML trial about to commence with Phase 1b results next year

post Posted: Apr 4 2016, 02:17 AM
  Quote Post

Posts: 9

In Reply To: maru's post @ Mar 22 2016, 12:39 AM

One of Deepest Clinical Pipelines on ASX - 3 clinical trials:

2 underway and 1 on track to initiate 1H 2016, all under IND Two Clinical Stage Oncology Drugs 2 drug candidates targeting key cancer pathways » Akt (PTX-200) and Ras (PTX-100)

Distinguished Scientific Provenance Compelling science from leading US institutions – Yale University & Moffitt Cancer Center

Significant investment already made Over $20 M invested to date » Technologies have been awarded multiple prestigious US government grants

Proven Leadership & Management Experienced and proven drug development team on board to aggressively drive product development

Rich Upcoming News Flow Multiple milestone announcements and valuation inflection points across all clinical programs over next 12 to 18 months

Robust IP Patents granted in major jurisdictions extending to 2030

post Posted: Mar 22 2016, 12:39 AM
  Quote Post

Posts: 9

In Reply To: maru's post @ Mar 10 2016, 11:08 PM

Directors holding around 11m shares which is around 12% of the 93.7m shares listed. Paul Hopper and his family owns the most with around 9m shares - interesting thing is he is Executive Chairman, Non Exec. Director of Imugene (IMU) and Chairman of Viralytics (VLA)

post Posted: Mar 10 2016, 11:08 PM
  Quote Post

Posts: 9

Recently on Bloomberg - several days ago - link Provided below

Also updated research report

The full report can be found under the Media/Press & Research Reports tab on the Company’s website or found on Edison Investment Limited’s website at by clicking to the Research tab, selecting Sector Reports and under the sector Health Care.

Shares Issued: 93,741,665

Market Cap: $8,905,458

Enough cash to last till year end , stock is worth a rerate compared to others valued much higher.


Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.